



GlaxoSmithKline Pharmaceuticals Limited
GSK House, Dr. Annie Besant Road,
Worli, Mumbai - 400 030
Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

5th June 2025

To,

BSE LIMITED

Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sir,

Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In terms of the requirements of Regulation 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has issued letters to those Shareholder's whose e-mail addresses are not registered with the Company/Depository Participants, providing the weblink from where the Annual Report can be accessed on the Company's website. The letter in this regard is enclosed herewith.

Kindly take the above intimation on your records.

Thanking you

Yours faithfully

For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni
Vice President – Administration, Real Estate
& Company Secretary

CIN: L24239MH1924PLC001151



GlaxoSmithKline Pharmaceuticals Limited

Registered Office: GSK House, Dr. Annie Besant Road, Worli, Mumbai 400030

CIN No.: L24239MH1924PLC001151 Tel: 022 24959595 Fax: 022 24959494

E-mail: in.investorquery@gsk.com; Website: <https://india-pharma.gsk.com/en-in/>

Date: June 3rd, 2025

Dear Shareholder,

Folio No: 0025492

Subject: Web-link of the Annual Report for the Financial Year ended 31 March 2025

In accordance with Regulation 36 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform that the Annual Report of the Company for the Financial Year ended 31 March 2025 has been emailed to the shareholders whose email address has been registered with the Depository Participants / Registrar and Transfer Agent (RTA).

In the absence of your email id being registered with the Depository Participant / RTA, pursuant to the Regulation 36(1)(b), please find below web-link to access the Annual Report of Company:

Web-link: <https://india-pharma.gsk.com/en-in/investors/annual-reports/>

As per SEBI guidelines, it is **mandatory for shareholders (including all joint shareholders)** to update their PAN, KYC details (including postal address with pin code, email address, mobile number, bank account details), and nomination details. We kindly request you to update your KYC and submit the required documents/information to your respective Depository Participant / RTA at the earliest convenience. Furthermore, any payments, including dividends, for folios where PAN or KYC details are not updated, will only be made electronically upon the registration of the required information.

We would also like to draw the attention of our shareholders to Senior Citizens Investor Cell which has been formed by our RTA, Kfintech Technologies Limited to assist exclusively the shareholders who are senior citizens (above 60 years of age) in redressing their grievances, complaints and queries. The senior citizens wishing to avail this service can send the communication to senior.citizen@kfintech.com. A dedicated toll-free number 1800 3094 006 is also provided for the convenience of the senior citizens.

We appreciate your prompt attention to this letter. For any queries or further assistance, please reach out to the RTA at inward.ris@kfintech.com.

For **GlaxoSmithKline Pharmaceuticals Limited**

SD/-

Ajay Nadkarni

**Vice President – Admin, Real
Estate & Company Secretary**